Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (1015)	3/15/2002 6:00:09 PM
From: scaram(o)uche	Respond to of 2243

Cool! I knew about the Chiron part, as Moos was V.P. R&D at Chiron (one of several, but the group that was focused on combichem and related stuff) and had established the Australian connection. But..... hmmmmm..... I thought that the Australian outfit had purchased a San Diego company?? But..... good! Thanks! Gotta run.

To: Icebrg who wrote (1015)	3/15/2002 6:00:31 PM
From: Icebrg	Read Replies (1) \| Respond to of 2243

Endorex (DOR) and Elan >>9 Nov 1999 Endorex Corporation has announced that its oral vaccine delivery joint venture with Elan Corporation, plc. had received notification from the U.S. Patent Office of the issuance of U.S. Patent No. 5,942,252 "Method for Delivering Bioactive Agents into and through the Mucosally- Associated Lymphoid Tissues and Controlling Their Release." The new patent describes methods for administering vaccine antigens, drugs, and other bioactive agents through mucosal tissues using biocompatible polymer microcapsules. The patent is one of a series of patents that the Endorex/Elan joint venture acquired earlier this year. The worldwide exclusive rights for the patent and the underlying technologies for the oral delivery of vaccines are licensed from the Southern Research Institute (SRI) and the University of Alabama at Birmingham Research Foundation (UABRF). The new patent is the sixth U.S. patent that has been issued on the underlying microsphere encapsulation technology originating at UABRF and SRI and adds to a portfolio of more than 45 international patents covering various aspects of innovative drug delivery technology. The issued claims describe the uses of microcapsules, which can encapsulate vaccine antigens, in size ranges that permit transport and uptake of the microcapsules by immune-sensitive tissue in the intestine and by other mucosal surfaces. "The issuance of this new SRI/UABRF patent further expands the joint venture's extensive oral vaccine delivery intellectual property, and allows us to have a strong patent position in the area of delivery of vaccines," said Michael S. Rosen, Chairman and President of the joint venture and Endorex President/CEO. Endorex and Elan formed the joint venture in January 1998 to develop new oral and mucosal delivery systems for delivery of human and veterinary vaccines, a $6 billion market. The joint venture is developing several microencapsulation technologies applicable to oral and mucosal administration of new and current vaccines.>> and >>Endorex to develop treatment for iron overload disorders 24 Feb 2000 Endorex Corporation has announced that its second joint venture (JV) with Elan Corporation, plc. has entered into a license, co-development, and supply agreement with Schein Pharmaceutical, Inc. The JV was established to exclusively research, develop and commercialise iron-chelating products using Elan's MEDIPAD Drug Delivery System. Under the terms of the agreement, the Elan/Endorex MEDIPAD JV grants to Schein Pharmaceutical a worldwide exclusive sub-license to utilize and commercialise the MEDIPAD Drug Delivery System to deliver a Schein Pharmaceutical iron chelator for the treatment of certain genetic blood disorders resulting from iron overload. In the United States, the groups will develop, in a program which includes the evaluation of clinical safety and efficacy, a drug/device combination product that will utilize the MEDIPAD Drug Delivery System to deliver the Schein Pharmaceutical iron chelator. After FDA approval, Schein Pharmaceutical will market the product in the United States and selected international markets. The groups together will identify sub-licensees for the international markets. The MEDIPAD Drug Delivery System that was developed by Elan is intended to be a minimally invasive micro-infusion pump, for self- administration in the home setting requiring minimal training. It is currently the only technology that combines the convenience of a skin patch with the delivery capabilities of an infusion pump. "We are very pleased that the JV will be working with Schein Pharmaceutical on this worldwide development and commercialisation program," said Michael Rosen, President and CEO of Endorex. "This relationship with Schein Pharmaceutical takes advantage of their research and development efforts related to iron chelators, and builds on their marketing expertise with physician groups treating iron-related disorders." "Once approved, this product may be a significant step forward in improving the manner in which these patients undergo iron chelator therapy and will enhance Schein's portfolio of iron management products," said Martin Sperber, Chairman and CEO, Schein Pharmaceutical. "This agreement with Schein Pharmaceutical marks another important milestone for the Elan/Endorex joint ventures and confirms the value of our partnering strategy. We are also very pleased that Elan's MEDIPAD technology will be used in conjuction with Schein Pharmaceutical's product to develop a new treatment for a chronic, life- threatening disease," stated Mike Sember, Executive Vice-President, Corporate Business Development, Elan Corporation, plc. >>